Heilongjiang ZBD Pharmaceutical Co Ltd (603567) - Net Assets
Based on the latest financial reports, Heilongjiang ZBD Pharmaceutical Co Ltd (603567) has net assets worth CN¥7.29 Billion CNY (≈ $1.07 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥11.80 Billion ≈ $1.73 Billion USD) and total liabilities (CN¥4.51 Billion ≈ $659.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Heilongjiang ZBD Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.29 Billion |
| % of Total Assets | 61.78% |
| Annual Growth Rate | 18.39% |
| 5-Year Change | 50.66% |
| 10-Year Change | 108.24% |
| Growth Volatility | 22.12 |
Heilongjiang ZBD Pharmaceutical Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Heilongjiang ZBD Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Heilongjiang ZBD Pharmaceutical Co Ltd assets under control for the complete picture of this company's asset base.
Annual Net Assets for Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual net assets of Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2024. For live valuation and market cap data, see market value of Heilongjiang ZBD Pharmaceutical Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.29 Billion ≈ $1.21 Billion |
+3.11% |
| 2023-12-31 | CN¥8.04 Billion ≈ $1.18 Billion |
+13.14% |
| 2022-12-31 | CN¥7.11 Billion ≈ $1.04 Billion |
+0.79% |
| 2021-12-31 | CN¥7.05 Billion ≈ $1.03 Billion |
+28.13% |
| 2020-12-31 | CN¥5.50 Billion ≈ $805.28 Million |
+4.82% |
| 2019-12-31 | CN¥5.25 Billion ≈ $768.26 Million |
+5.36% |
| 2018-12-31 | CN¥4.98 Billion ≈ $729.21 Million |
+6.50% |
| 2017-12-31 | CN¥4.68 Billion ≈ $684.71 Million |
+8.65% |
| 2016-12-31 | CN¥4.31 Billion ≈ $630.20 Million |
+8.16% |
| 2015-12-31 | CN¥3.98 Billion ≈ $582.63 Million |
+83.26% |
| 2014-12-31 | CN¥2.17 Billion ≈ $317.92 Million |
+24.36% |
| 2013-12-31 | CN¥1.75 Billion ≈ $255.64 Million |
+32.43% |
| 2012-12-31 | CN¥1.32 Billion ≈ $193.04 Million |
+42.91% |
| 2011-12-31 | CN¥923.09 Million ≈ $135.08 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Heilongjiang ZBD Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1518.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.06 Billion | 52.05% |
| Common Stock | CN¥941.14 Million | 12.06% |
| Other Comprehensive Income | CN¥4.99 Million | 0.06% |
| Other Components | CN¥2.79 Billion | 35.82% |
| Total Equity | CN¥7.80 Billion | 100.00% |
Heilongjiang ZBD Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Heilongjiang ZBD Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangdong LingXiao Pump Industry Co Ltd
SHE:002884
|
$992.89 Million |
|
Dongfeng Electronic Technology Co Ltd
SHG:600081
|
$992.95 Million |
|
Beijing Asiacom Information Technology Co.Ltd
SHE:301085
|
$993.37 Million |
|
AcadeMedia AB (publ)
ST:ACAD
|
$993.50 Million |
|
Chongqing Wangbian Electric (Group) Corp. Ltd.
SHG:603191
|
$992.61 Million |
|
Suzhou Xianglou New Material Co. Ltd.
SHE:301160
|
$992.44 Million |
|
Dongguan Kingsun Optoelectronic Co Ltd
SHE:002638
|
$992.23 Million |
|
Shenzhen Sunmoon Microelectronics Co. Ltd. A
SHG:688699
|
$992.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Heilongjiang ZBD Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,548,383,235 to 7,800,611,827, a change of 252,228,592 (3.3%).
- Net income of 438,216,198 contributed positively to equity growth.
- Dividend payments of 324,278,240 reduced retained earnings.
- Other comprehensive income increased equity by 1,052,324.
- Other factors increased equity by 137,238,310.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥438.22 Million | +5.62% |
| Dividends Paid | CN¥324.28 Million | -4.16% |
| Other Comprehensive Income | CN¥1.05 Million | +0.01% |
| Other Changes | CN¥137.24 Million | +1.76% |
| Total Change | CN¥- | 3.34% |
Book Value vs Market Value Analysis
This analysis compares Heilongjiang ZBD Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.87x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.64x to 0.87x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥1.28 | CN¥7.21 | x |
| 2012-12-31 | CN¥1.82 | CN¥7.21 | x |
| 2013-12-31 | CN¥2.42 | CN¥7.21 | x |
| 2014-12-31 | CN¥3.04 | CN¥7.21 | x |
| 2015-12-31 | CN¥5.20 | CN¥7.21 | x |
| 2016-12-31 | CN¥5.07 | CN¥7.21 | x |
| 2017-12-31 | CN¥5.50 | CN¥7.21 | x |
| 2018-12-31 | CN¥5.86 | CN¥7.21 | x |
| 2019-12-31 | CN¥6.17 | CN¥7.21 | x |
| 2020-12-31 | CN¥6.47 | CN¥7.21 | x |
| 2021-12-31 | CN¥8.15 | CN¥7.21 | x |
| 2022-12-31 | CN¥7.54 | CN¥7.21 | x |
| 2023-12-31 | CN¥8.03 | CN¥7.21 | x |
| 2024-12-31 | CN¥8.30 | CN¥7.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Heilongjiang ZBD Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.62%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.21%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.63x
- Recent ROE (5.62%) is below the historical average (13.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 32.07% | 27.64% | 0.74x | 1.56x | CN¥203.75 Million |
| 2012 | 29.68% | 28.24% | 0.65x | 1.62x | CN¥258.37 Million |
| 2013 | 24.97% | 30.88% | 0.44x | 1.86x | CN¥261.94 Million |
| 2014 | 21.81% | 29.96% | 0.44x | 1.65x | CN¥258.45 Million |
| 2015 | 14.62% | 28.23% | 0.35x | 1.49x | CN¥185.01 Million |
| 2016 | 11.85% | 21.31% | 0.37x | 1.49x | CN¥79.44 Million |
| 2017 | 11.15% | 16.61% | 0.46x | 1.47x | CN¥53.93 Million |
| 2018 | 9.30% | 16.63% | 0.34x | 1.65x | CN¥-34.82 Million |
| 2019 | 7.80% | 12.41% | 0.37x | 1.72x | CN¥-115.58 Million |
| 2020 | 7.94% | 12.82% | 0.33x | 1.86x | CN¥-113.16 Million |
| 2021 | 4.72% | 8.05% | 0.36x | 1.63x | CN¥-372.19 Million |
| 2022 | 2.61% | 4.40% | 0.36x | 1.64x | CN¥-524.45 Million |
| 2023 | 6.26% | 15.06% | 0.25x | 1.65x | CN¥-282.10 Million |
| 2024 | 5.62% | 16.21% | 0.21x | 1.63x | CN¥-341.84 Million |
Industry Comparison
This section compares Heilongjiang ZBD Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,691,234,838
- Average return on equity (ROE) among peers: 6.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Heilongjiang ZBD Pharmaceutical Co Ltd (603567) | CN¥7.29 Billion | 32.07% | 0.62x | $992.80 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $903.62 Million | 4.28% | 2.45x | $1.16 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.22 Billion | 5.35% | 1.27x | $441.99 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $9.87 Billion | 20.71% | 0.25x | $5.01 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.80 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $3.04 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $9.03 Billion | 25.71% | 0.43x | $13.75 Billion |
| Hainan Haiyao Co Ltd (000566) | $275.57 Million | 17.28% | 1.12x | $947.33 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $231.22 Million | -38.13% | 1.23x | $389.67 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.29 Billion | 2.31% | 2.07x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.32 Billion |
About Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.